Drugs / Quadrivalent Subunit Influenza Vaccine (Adjuvant)
Quadrivalent Subunit Influenza Vaccine (Adjuvant)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07421037 | Nov 2025 → Dec 2026 expected | influenza | Ab&B Bio-tech Co., Ltd.JS | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Quadrivalent Subunit Influenza Vaccine (Adjuvant) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07421037 ↗ |
| Modality | Vaccine | “Quadrivalent Subunit Influenza Vaccine (Adjuvant)” NCT07421037 ↗ |
| Route | Intramuscular | “A single 0.25 mL dose is administered intramuscularly into the deltoid muscle of the upper arm on Day 0.” NCT07421037 ↗ |